Search

Displaying results 4311 - 4320 of 7502 in total
  1. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  2. Drug

    Inosine pranobex

    go.drugbank.com/drugs/DB13156
    Approved

    Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

  3. Drug

    AG-858

    go.drugbank.com/drugs/DB05502
    Investigational

    Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

  4. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

  5. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and periphe...

    Products: NATIL N 5MG, NATIL N 10MG
  6. Drug

    Pentolinium

    go.drugbank.com/drugs/DB01090
    Approved

    Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.

  7. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Lipids promote the fusion of liposomes to cells. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  8. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]

  9. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  10. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.